United States fund KKR to invest ₹2,000 crore in Reliance Retail to hike stake

FDA Warns Companies to, Stop Selling Potentially Dangerous, , Unapproved Eye Drops. Gizmodo reports that the United States Food and Drug Administration (FDA) has warned several companies to stop selling unapproved eye drop products. On September 12, the FDA announced that it had issued warning letters to eight companies regarding the potentially dangerous products. The companies, including major retail chains CVS and Walgreens, have allegedly committed a number of violations by marketing or manufacturing these products. The companies, including major retail chains CVS and Walgreens, have allegedly committed a number of violations by marketing or manufacturing these products. The companies, including major retail chains CVS and Walgreens, have allegedly committed a number of violations by marketing or manufacturing these products. The FDA has also expressed concerns over silver compounds found in some of the products, which can turn people's skin or eyes blue with long-term use. According to the FDA, some of the eye drop products were allegedly manufactured at facilities that have failed to meet standard safety and quality guidelines. The FDA is particularly concerned that these illegally marketed, unapproved ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses, Food and Drug Administration, via statement. The FDA is particularly concerned that these illegally marketed, unapproved ophthalmic drug products pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses, Food and Drug Administration, via statement. Gizmodo reports that the companies have 15 days to respond with their plans to correct the alleged violations. If the companies fail to respond, the FDA could take further action to either seize or stop the manufacturing of the products in question. When we identify illegally marketed, unapproved drugs and lapses in drug quality that pose potential risks, the FDA works to notify the companies involved of the violations, Jill Furman, Director of the Office of Compliance for the FDA’s Center for Drug Evaluation and Research, via Gizmodo. We will continue to investigate potentially harmful eye products and work to ensure violative products stay off store shelves so that consumers can continue taking the medicines they need without concern, Jill Furman, Director of the Office of Compliance for the FDA’s Center for Drug Evaluation and Research, via Gizmodo. We will continue to investigate potentially harmful eye products and work to ensure violative products stay off store shelves so that consumers can continue taking the medicines they need without concern, Jill Furman, Director of the Office of Compliance for the FDA’s Center for Drug Evaluation and Research, via Gizmodo

In 2020, Reliance Retail raised $5.71 billion by selling a 10.09% stake to investors including KKR, the Saudi Public Investment Fund, General Atlantic and the...